Influenza is an infectious disease and affects the upper respiratory tract in humans. The disease is common in children and elderly population (aged 65 years and above). The disease has a huge impact on Public Company health. Influenza A virus poses a greater risk as compared to the influenza B virus. The B virus is responsible for 20% to 25% of infections globally. Proper collection, storage and transport of respiratory specimens are the essential first step for laboratory detection of influenza virus infections. Laboratory confirmation of influenza virus from throat, nasal and nasopharyngeal secretions or tracheal aspirate or washings is commonly performed using direct antigen detection, virus isolation, or detection of influenza-specific RNA by reverse transcriptase-polymerase chain reaction (RT-PCR).
Highlights
The global Influenza Diagnostics market was valued at US$ 2495.1 million in 2022 and is anticipated to reach US$ 3599.9 million by 2029, witnessing a CAGR of 6.3% during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North America is the largest consumption place, with a consumption marker share nearly 53%. Following North America, Europe is the second largest consumption place with the consumption market share of 25%.
The main manufacturers are BD, Abbott (Include Alere), Roche, SIEMENS, Analytik Jena, Quidel, Thermo Fisher, Meridian Bioscience, BioMerieux, Sekisui Diagnostics, Response Biomedical, SA Scientific etc. BD is the largest manufacturer with about 19% market share.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Influenza Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Influenza Diagnostics.
The Influenza Diagnostics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Influenza Diagnostics market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Influenza Diagnostics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
BD
Abbott (Include Alere)
Roche
SIEMENS
Analytik Jena
Quidel
Thermo Fisher
Meridian Bioscience
BioMerieux
Sekisui Diagnostics
Response Biomedical
SA Scientific
Segment by Type
RIDT
RT-PCR
Cell Culture
Others
Segment by Application
Hospitals
POCT
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Influenza Diagnostics companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Influenza Diagnostics 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 RIDT
1.2.3 RT-PCR
1.2.4 Cell Culture
1.2.5 Others
1.3 麻豆原创 by Application
1.3.1 Global Influenza Diagnostics 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospitals
1.3.3 POCT
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Influenza Diagnostics 麻豆原创 Perspective (2018-2029)
2.2 Influenza Diagnostics Growth Trends by Region
2.2.1 Global Influenza Diagnostics 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Influenza Diagnostics Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Influenza Diagnostics Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Influenza Diagnostics 麻豆原创 Dynamics
2.3.1 Influenza Diagnostics Industry Trends
2.3.2 Influenza Diagnostics 麻豆原创 Drivers
2.3.3 Influenza Diagnostics 麻豆原创 Challenges
2.3.4 Influenza Diagnostics 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Influenza Diagnostics Players by Revenue
3.1.1 Global Top Influenza Diagnostics Players by Revenue (2018-2023)
3.1.2 Global Influenza Diagnostics Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Influenza Diagnostics 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Influenza Diagnostics Revenue
3.4 Global Influenza Diagnostics 麻豆原创 Concentration Ratio
3.4.1 Global Influenza Diagnostics 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Influenza Diagnostics Revenue in 2022
3.5 Influenza Diagnostics Key Players Head office and Area Served
3.6 Key Players Influenza Diagnostics Product Solution and Service
3.7 Date of Enter into Influenza Diagnostics 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Influenza Diagnostics Breakdown Data by Type
4.1 Global Influenza Diagnostics Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Influenza Diagnostics Forecasted 麻豆原创 Size by Type (2024-2029)
5 Influenza Diagnostics Breakdown Data by Application
5.1 Global Influenza Diagnostics Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Influenza Diagnostics Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Influenza Diagnostics 麻豆原创 Size (2018-2029)
6.2 North America Influenza Diagnostics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Influenza Diagnostics 麻豆原创 Size by Country (2018-2023)
6.4 North America Influenza Diagnostics 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Influenza Diagnostics 麻豆原创 Size (2018-2029)
7.2 Europe Influenza Diagnostics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Influenza Diagnostics 麻豆原创 Size by Country (2018-2023)
7.4 Europe Influenza Diagnostics 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Influenza Diagnostics 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Influenza Diagnostics 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Influenza Diagnostics 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Influenza Diagnostics 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Influenza Diagnostics 麻豆原创 Size (2018-2029)
9.2 Latin America Influenza Diagnostics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Influenza Diagnostics 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Influenza Diagnostics 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Influenza Diagnostics 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Influenza Diagnostics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Influenza Diagnostics 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Influenza Diagnostics 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 BD
11.1.1 BD Company Detail
11.1.2 BD Business Overview
11.1.3 BD Influenza Diagnostics Introduction
11.1.4 BD Revenue in Influenza Diagnostics Business (2018-2023)
11.1.5 BD Recent Development
11.2 Abbott (Include Alere)
11.2.1 Abbott (Include Alere) Company Detail
11.2.2 Abbott (Include Alere) Business Overview
11.2.3 Abbott (Include Alere) Influenza Diagnostics Introduction
11.2.4 Abbott (Include Alere) Revenue in Influenza Diagnostics Business (2018-2023)
11.2.5 Abbott (Include Alere) Recent Development
11.3 Roche
11.3.1 Roche Company Detail
11.3.2 Roche Business Overview
11.3.3 Roche Influenza Diagnostics Introduction
11.3.4 Roche Revenue in Influenza Diagnostics Business (2018-2023)
11.3.5 Roche Recent Development
11.4 SIEMENS
11.4.1 SIEMENS Company Detail
11.4.2 SIEMENS Business Overview
11.4.3 SIEMENS Influenza Diagnostics Introduction
11.4.4 SIEMENS Revenue in Influenza Diagnostics Business (2018-2023)
11.4.5 SIEMENS Recent Development
11.5 Analytik Jena
11.5.1 Analytik Jena Company Detail
11.5.2 Analytik Jena Business Overview
11.5.3 Analytik Jena Influenza Diagnostics Introduction
11.5.4 Analytik Jena Revenue in Influenza Diagnostics Business (2018-2023)
11.5.5 Analytik Jena Recent Development
11.6 Quidel
11.6.1 Quidel Company Detail
11.6.2 Quidel Business Overview
11.6.3 Quidel Influenza Diagnostics Introduction
11.6.4 Quidel Revenue in Influenza Diagnostics Business (2018-2023)
11.6.5 Quidel Recent Development
11.7 Thermo Fisher
11.7.1 Thermo Fisher Company Detail
11.7.2 Thermo Fisher Business Overview
11.7.3 Thermo Fisher Influenza Diagnostics Introduction
11.7.4 Thermo Fisher Revenue in Influenza Diagnostics Business (2018-2023)
11.7.5 Thermo Fisher Recent Development
11.8 Meridian Bioscience
11.8.1 Meridian Bioscience Company Detail
11.8.2 Meridian Bioscience Business Overview
11.8.3 Meridian Bioscience Influenza Diagnostics Introduction
11.8.4 Meridian Bioscience Revenue in Influenza Diagnostics Business (2018-2023)
11.8.5 Meridian Bioscience Recent Development
11.9 BioMerieux
11.9.1 BioMerieux Company Detail
11.9.2 BioMerieux Business Overview
11.9.3 BioMerieux Influenza Diagnostics Introduction
11.9.4 BioMerieux Revenue in Influenza Diagnostics Business (2018-2023)
11.9.5 BioMerieux Recent Development
11.10 Sekisui Diagnostics
11.10.1 Sekisui Diagnostics Company Detail
11.10.2 Sekisui Diagnostics Business Overview
11.10.3 Sekisui Diagnostics Influenza Diagnostics Introduction
11.10.4 Sekisui Diagnostics Revenue in Influenza Diagnostics Business (2018-2023)
11.10.5 Sekisui Diagnostics Recent Development
11.11 Response Biomedical
11.11.1 Response Biomedical Company Detail
11.11.2 Response Biomedical Business Overview
11.11.3 Response Biomedical Influenza Diagnostics Introduction
11.11.4 Response Biomedical Revenue in Influenza Diagnostics Business (2018-2023)
11.11.5 Response Biomedical Recent Development
11.12 SA Scientific
11.12.1 SA Scientific Company Detail
11.12.2 SA Scientific Business Overview
11.12.3 SA Scientific Influenza Diagnostics Introduction
11.12.4 SA Scientific Revenue in Influenza Diagnostics Business (2018-2023)
11.12.5 SA Scientific Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
BD
Abbott (Include Alere)
Roche
SIEMENS
Analytik Jena
Quidel
Thermo Fisher
Meridian Bioscience
BioMerieux
Sekisui Diagnostics
Response Biomedical
SA Scientific
听
听
*If Applicable.
